Cargando…

Long-Term Outcome with New Generation Prostheses in Patients Undergoing Transcatheter Aortic Valve Replacement

The aim of this study was to compare patients with transcatheter aortic valve replacement (TAVR) receiving new generation prostheses SAPIEN 3 (S3, Edwards Lifesc.) and Evolut R (ER, Medtronic Inc.) in terms of periprocedural and long-term outcome. Our retrospective, single-center analysis included 3...

Descripción completa

Detalles Bibliográficos
Autores principales: Tamm, Alexander R., Geyer, Martin, Kreidel, Felix, Dausmann, Lea, Jablonski, Caroline, Hahad, Omar, Schulz, Eberhard, Münzel, Thomas, Von Bardeleben, Ralph Stephan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8303957/
https://www.ncbi.nlm.nih.gov/pubmed/34300268
http://dx.doi.org/10.3390/jcm10143102
_version_ 1783727216333422592
author Tamm, Alexander R.
Geyer, Martin
Kreidel, Felix
Dausmann, Lea
Jablonski, Caroline
Hahad, Omar
Schulz, Eberhard
Münzel, Thomas
Von Bardeleben, Ralph Stephan
author_facet Tamm, Alexander R.
Geyer, Martin
Kreidel, Felix
Dausmann, Lea
Jablonski, Caroline
Hahad, Omar
Schulz, Eberhard
Münzel, Thomas
Von Bardeleben, Ralph Stephan
author_sort Tamm, Alexander R.
collection PubMed
description The aim of this study was to compare patients with transcatheter aortic valve replacement (TAVR) receiving new generation prostheses SAPIEN 3 (S3, Edwards Lifesc.) and Evolut R (ER, Medtronic Inc.) in terms of periprocedural and long-term outcome. Our retrospective, single-center analysis included 359 consecutive patients with severe aortic stenosis who underwent TAVR with S3 or ER from 2014–2016 (mean age 82 ± 7 years, 47% male, mean EuroSCORE II 8.0 ± 8%, mean follow-up 3.8 years). Device Success was equal (S3 93.0% vs. ER 92.4%, p = 0.812). We report a 30-day mortality of 2.8% in the S3 group, and 2.1% in the ER group (p = 0.674). There was no difference in stroke, conversion to open surgery, vascular and bleeding complications or myocardial infarction. While prosthesis mean gradients were higher with S3 (12.0 mmHg vs. 8.2 mmHg, p < 0.001), there was a trend to less paravalvular regurgitation (PVR moderate or severe: 1% vs. 3.6%, p = 0.088). All-cause mortality up to 5 years did not show a difference (mean survival S3 3.5 ± 0.24 years, ER 3.3 ± 0.29 years, p = 0.895). Independent predictors of long-term mortality were impaired LVEF, chronic kidney injury, peripheral artery disease, malignant tumor and periprocedural stroke. New generation TAVR valves offer an excellent implant and outcome success rate. Long-term survival was independent of prostheses choice and mainly attributed to comorbidities and complications.
format Online
Article
Text
id pubmed-8303957
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-83039572021-07-25 Long-Term Outcome with New Generation Prostheses in Patients Undergoing Transcatheter Aortic Valve Replacement Tamm, Alexander R. Geyer, Martin Kreidel, Felix Dausmann, Lea Jablonski, Caroline Hahad, Omar Schulz, Eberhard Münzel, Thomas Von Bardeleben, Ralph Stephan J Clin Med Article The aim of this study was to compare patients with transcatheter aortic valve replacement (TAVR) receiving new generation prostheses SAPIEN 3 (S3, Edwards Lifesc.) and Evolut R (ER, Medtronic Inc.) in terms of periprocedural and long-term outcome. Our retrospective, single-center analysis included 359 consecutive patients with severe aortic stenosis who underwent TAVR with S3 or ER from 2014–2016 (mean age 82 ± 7 years, 47% male, mean EuroSCORE II 8.0 ± 8%, mean follow-up 3.8 years). Device Success was equal (S3 93.0% vs. ER 92.4%, p = 0.812). We report a 30-day mortality of 2.8% in the S3 group, and 2.1% in the ER group (p = 0.674). There was no difference in stroke, conversion to open surgery, vascular and bleeding complications or myocardial infarction. While prosthesis mean gradients were higher with S3 (12.0 mmHg vs. 8.2 mmHg, p < 0.001), there was a trend to less paravalvular regurgitation (PVR moderate or severe: 1% vs. 3.6%, p = 0.088). All-cause mortality up to 5 years did not show a difference (mean survival S3 3.5 ± 0.24 years, ER 3.3 ± 0.29 years, p = 0.895). Independent predictors of long-term mortality were impaired LVEF, chronic kidney injury, peripheral artery disease, malignant tumor and periprocedural stroke. New generation TAVR valves offer an excellent implant and outcome success rate. Long-term survival was independent of prostheses choice and mainly attributed to comorbidities and complications. MDPI 2021-07-14 /pmc/articles/PMC8303957/ /pubmed/34300268 http://dx.doi.org/10.3390/jcm10143102 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Tamm, Alexander R.
Geyer, Martin
Kreidel, Felix
Dausmann, Lea
Jablonski, Caroline
Hahad, Omar
Schulz, Eberhard
Münzel, Thomas
Von Bardeleben, Ralph Stephan
Long-Term Outcome with New Generation Prostheses in Patients Undergoing Transcatheter Aortic Valve Replacement
title Long-Term Outcome with New Generation Prostheses in Patients Undergoing Transcatheter Aortic Valve Replacement
title_full Long-Term Outcome with New Generation Prostheses in Patients Undergoing Transcatheter Aortic Valve Replacement
title_fullStr Long-Term Outcome with New Generation Prostheses in Patients Undergoing Transcatheter Aortic Valve Replacement
title_full_unstemmed Long-Term Outcome with New Generation Prostheses in Patients Undergoing Transcatheter Aortic Valve Replacement
title_short Long-Term Outcome with New Generation Prostheses in Patients Undergoing Transcatheter Aortic Valve Replacement
title_sort long-term outcome with new generation prostheses in patients undergoing transcatheter aortic valve replacement
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8303957/
https://www.ncbi.nlm.nih.gov/pubmed/34300268
http://dx.doi.org/10.3390/jcm10143102
work_keys_str_mv AT tammalexanderr longtermoutcomewithnewgenerationprosthesesinpatientsundergoingtranscatheteraorticvalvereplacement
AT geyermartin longtermoutcomewithnewgenerationprosthesesinpatientsundergoingtranscatheteraorticvalvereplacement
AT kreidelfelix longtermoutcomewithnewgenerationprosthesesinpatientsundergoingtranscatheteraorticvalvereplacement
AT dausmannlea longtermoutcomewithnewgenerationprosthesesinpatientsundergoingtranscatheteraorticvalvereplacement
AT jablonskicaroline longtermoutcomewithnewgenerationprosthesesinpatientsundergoingtranscatheteraorticvalvereplacement
AT hahadomar longtermoutcomewithnewgenerationprosthesesinpatientsundergoingtranscatheteraorticvalvereplacement
AT schulzeberhard longtermoutcomewithnewgenerationprosthesesinpatientsundergoingtranscatheteraorticvalvereplacement
AT munzelthomas longtermoutcomewithnewgenerationprosthesesinpatientsundergoingtranscatheteraorticvalvereplacement
AT vonbardelebenralphstephan longtermoutcomewithnewgenerationprosthesesinpatientsundergoingtranscatheteraorticvalvereplacement